Roivant Sciences Ltd
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 6.1% | 1.3% | 15.3% | 5.2% | 5.2% | 2.9% | 2.7% | 7.1% | 7.1% | 35.0% | 12.7% | 19.7% | 18.8% | |
| 93.9% | 98.7% | 84.7% | 94.8% | 94.8% | 97.1% | 97.3% | 92.9% | 92.9% | 65.0% | 87.3% | 80.3% | 81.2% | |
| 3,146.7% | 694.9% | 417.9% | 3,197.2% | 3,181.0% | 1,570.1% | 1,918.6% | 7,047.0% | 10,475.4% | 8,273.1% | 7,894.6% | 14,009.4% | 9,704.0% | |
| 2,428.1% | 823.6% | 681.9% | 4,533.7% | 4,533.7% | 1,569.6% | 1,943.1% | 6,176.0% | 9,110.4% | 8,758.0% | 6,279.8% | 11,479.0% | 8,523.3% | |
| 5,957.1% | -32,849.8% | 1,004.2% | 7,730.8% | 7,730.8% | 3,139.7% | 3,861.7% | 13,222.9% | 19,585.8% | 17,031.1% | 14,174.4% | 25,461.2% | 18,222.1% | |
| -5,863.2% | 32,948.6% | -919.5% | -7,636.0% | -7,636.0% | -3,042.6% | -3,764.4% | -13,130.0% | -19,492.9% | -16,966.1% | -14,087.1% | -25,380.9% | -18,140.9% | |
| 253.5% | 60.7% | 24.8% | 299.4% | 299.4% | – | – | – | – | – | – | – | – | |
| -6,617.5% | 33,116.2% | -661.8% | -5,014.1% | -5,014.1% | -2,600.5% | -2,682.4% | -12,408.4% | -10,123.7% | -14,525.7% | 18,019.7% | -20,427.5% | -3,848.6% | |
| 88.7% | 143.7% | -31.0% | 278.4% | 278.4% | -283.5% | 651.5% | 214.2% | 445.3% | 1,167.2% | 3,902.9% | -274.9% | 1,655.8% | |
| -8,342.3% | 32,747.6% | -522.3% | -5,143.8% | -5,143.8% | 1,878.3% | -2,727.5% | -10,292.9% | -7,225.9% | -13,301.2% | 12,023.6% | -13,164.4% | -3,534.9% | |
| -5,327.7% | -1,385.2% | -618.9% | -4,905.9% | -4,973.5% | -2,568.1% | -2,663.5% | -12,357.8% | -10,065.1% | -14,491.1% | 18,045.0% | -19,991.2% | -3,735.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.